Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab or Merestinib plus Gemcitabine and Cisplatin vs Placebo in First-Line Advanced Biliary Tract Cancer
2015-004699-31Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in biliary cancer and hepatobiliary neoplasm comparing Ramucirumab arm, Merestinib arm and Placebo arm (3 arms). Primary endpoint: Progression-free survival. Started Feb 2016; status: completed.
02
Drugs
ramucirumabmerestinib
03
Conditions
biliary cancerhepatobiliary neoplasm
Beyond the preview
Go deeper on 2015-004699-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004699-31.